XTAE
REKA
Market cap40mUSD
Oct 07, Last price
1,071.00ILS
1D
-2.28%
1Q
0.85%
Jan 2017
-48.68%
Name
Rekah Pharmaceutical Industry Ltd
Chart & performance
P/E
—
P/S
0.41
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
2.54%
Revenues
301m
-6.44%
Net income
-18m
L
CFO
13m
-51.21%
Dividend
Apr 06, 202286.776 ILS/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Rekah Pharmaceutical Industry Ltd., established in 1941 and headquartered in Holon, Israel, specializes in the production, marketing, distribution, and sale of a broad spectrum of healthcare items across Israel. The company's offerings include both prescription and over-the-counter medicines, dermo-cosmetic products, vitamins, and nutritional supplements. Its extensive portfolio comprises approximately 280 distinct pharmaceutical drugs used in various medical sectors. These encompass steroid tablets, antibiotics (such as penicillin and cephalosporin), eye drops and ointments for allergies, infections, and dryness, baby products, and dermatological treatments.
Key people
Yuval Elgrably
Deputy Chief Executive Officer · since 2013
Haim Cohen
Chief Financial Officer
Yuval Bernshtein
Vice President - Finance · since 2018
Menachem Dasberg
Vice President-Economic Division Manager · since 2014
Georgette Elgrably
Head of Industrial Division, Director · since 2015
Ronit Zelnik
Head of Projects Division
Chairman of the Board · since 2015
Director · since 2015
Director · since 2015
Arye Elgrably
Chief Executive Officer, Director · since 2015
External Director · since 2016
External Director · since 2015
Arnon Zuaretz
External Director · since 2016
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||